AbbVie

Immunomedics strives to improve health care and extend life by focusing on the development and commercialization of humanized monoclonal antibody-based treatments for cancer, autoimmune and other serious diseases. The Food and Drug Administration recently fast tracked the company s leading drug candidate, Epratuzumab for the potential treatment of the world s estimated 3 million sufferers of lupus. Immunomedics is traded publicly on NASDAQ under the symbol IMMU and maintains corporate headquarters in Morris Plains, N.J.

Eisai is a pharmaceutical subsidiary of Tokyo-based Eisai Company, is a research-based human health care organization that serves clients throughout the world. The company has been in operation since 1995 and markets products throughout the United States. With sales revenue of more than $3 billion, it serves patients and caregivers. The company works with health care professionals, hospitals and managed care organizations. It employs a staff of over 1,800 people. The company markets products for the treatment of neurological and gastrointestinal disorders. It offers products under the ARICEPT, ACIPHEX, BANZEL, ZONEGRAN and FRAGMIN brands. Eisai maintains a pharmaceutical production and formulation research and development facility in North Carolina. The company s distributors include Caremark and Morris & Dickson Company.